| Literature DB >> 29434915 |
Kohei Ono1,2, Eisuke Shiozawa1, Nobuyuki Ohike3, Tomonori Fujii1,2, Hideki Shibata1,2, Tetsuya Kitajima1,2, Koichiro Fujimasa1,2, Naoko Okamoto1, Yukiko Kawaguchi1, Tasuku Nagumo1, Sakiko Tazawa1, Mayumi Homma1, Toshiko Yamochi-Onizuka1, Tomoko Norose3, Hitoshi Yoshida4, Masahiko Murakami2, Gensyu Tate1, Masafumi Takimoto1.
Abstract
The WHO 2010 classification divides gastrointestinal neuroendocrine neoplasms (GI-NENs) into neuroendocrine tumor (NET) G1, NET G2, neuroendocrine carcinoma (NEC) and mixed adenoendocrine carcinoma (MANEC) groups. A total of 136 cases of GI-NENs diagnosed at our hospitals as gastrointestinal carcinoids, endocrine cell carcinomas and NENs over the last 11 years, using the WHO 2010 classification were assessed. Among the 136 cases, 88.2% (120/136) were classified into the NET group (NET G1/G2) and 11.8% (16/136) were classified into the NEC group (NEC/MANEC). The incidences of lymphatic and venous invasions were higher in the NEC group compared with in the NET group (P<0.0001 and P=0.0021, respectively). The immunohistochemical staining of cluster of differentiation 73 (CD73) was evaluated in GI-NENs. CD73 is a potentially useful molecule in tumor immunity. In general, CD73 on the tumor cell membrane converts adenosine monophosphate to adenosine, which restrains the production of interferon-γ and cytocidal activity. Although the association between stem cells of pancreatic NENs and CD73 has been reported, few studies have reported on CD73 expression in GI-NENs. Immunohistochemical CD73 expression on the cytomembrane of neuroendocrine cells was detected in 27.2% (37/136) of the GI-NENs. The positive ratio of CD73 was significantly higher in the NEC group compared with in the NET group (P=0.0015). CD73 is also considered as a potential biomarker of anti-programmed death-1 (PD-1) therapy. The expression of programmed death-ligand 1 (PD-L1) on the cytomembrane of GI-NENs was assessed. The positive ratio of PD-L1 was higher in the NEC group compared with in the NET group (P=0.0011). Furthermore, CD73 expression status was significantly correlated with PD-L1 expression (P<0.0001). These results indicate that CD73 may be an interesting candidate for a biomarker for certain prognostic factors and therapeutics concerning PD-1 therapy.Entities:
Keywords: WHO2010 classification; cluster of differentiation 73; gastrointestinal neuroendocrine neoplasms; immunohistochemical staining; programmed death-1
Year: 2017 PMID： 29434915 PMCID： PMC5776938 DOI： 10.3892/ol.2017.7569
Source DB: PubMed Journal: Oncol Lett ISSN： 1792-1074 Impact factor: 2.967